Last updated: February 9, 2026
Litigation Summary and Analysis for Purdue Pharma L.P. v. Kashiv Pharma, LLC
Case Overview and Status
Purdue Pharma L.P. filed suit against Kashiv Pharma LLC in the U.S. District Court for the District of Delaware (Case No. 1:18-cv-00052). The lawsuit centers on patent infringement allegations regarding Purdue's proprietary formulation for opioid medication and Kashiv's competing product.
As of the latest court filings, the case remains active with ongoing discovery and motions. No final judgment has been issued.
Core Allegations
Purdue asserts that Kashiv infringed its patents related to a specific formulation of oxycodone, which Purdue holds under U.S. Patent No. 9,839,933. The patent claims cover a controlled-release opioid formulation designed to reduce abuse potential and improve bioavailability.
Kashiv allegedly launched a generic version of the Purdue product before patent expiration, infringing on Purdue's rights. Purdue seeks injunctive relief, damages for patent infringement, and attorneys' fees.
Patent Details and Scope
- Patent No.: 9,839,933
- Filing Date: March 3, 2017
- Issue Date: December 12, 2017
- Claims Cover: Controlled-release oxycodone formulations with specific excipients and manufacturing processes aimed at abuse-deterrence.
The patent claims are narrow, focusing on the precise composition and method of manufacturing, which Purdue argues Kashiv's product infringes upon by employing substantially identical techniques.
Defendant's Position
Kashiv denies infringement, asserting its formulation does not violate Purdue's patent claims. Kashiv claims its product uses different excipients and an alternative manufacturing process, thus falling outside the patent's scope. The defendant also challenges the validity of Purdue's patent, arguing prior art and obviousness.
Legal Points
- Infringement Analysis: Purdue claims direct infringement via Kashiv’s product, with potential inducement and contributory infringement claims.
- Validity Challenges: Kashiv has filed motions to invalidate the patent based on prior art references, including earlier formulations and published research.
- Relief Sought: An injunction prohibiting Kashiv from manufacturing the infringing product, damages, and legal costs.
Procedure and Current Status
- Initial Motions: Both parties filed preliminary motions, including Purdue’s motion for a preliminary injunction, which was denied in December 2020 due to insufficient evidence of imminent irreparable harm.
- Discovery: Extensive document exchanges and depositions have taken place since 2018. Patent validity and infringement are key issues.
- Trials or Hearings: No trial date has been set; the case remains in pre-trial phase with scheduled expert reports and potential dispositive motions.
Comparative Context
Patent infringement suits within the opioid manufacturing sector have increased, especially when patents for abuse-deterrent formulations are involved. Purdue’s focus on proprietary formulations aims to extend market exclusivity beyond patent terms through litigation. The case reflects common issues around patent validity, infringement, and the interplay of generic drug entry and patent rights.
Implications for Industry
- Patent disputes persist amid increased generic penetration into the opioid market.
- Patent validity challenges are prominent, especially when allegations of obviousness or prior art are involved.
- Litigation delays and disputes contribute to the complex landscape of opioid patent protections and market competition.
Key Takeaways
- The Purdue v. Kashiv case centers on patent rights over abuse-deterrent opioids.
- Purdue alleges Kashiv's product infringes on its '933 patent; Kashiv disputes infringement and validity.
- The case is in discovery, with no trial scheduled, but motions and validity challenges advance.
- Patent disputes are a significant element controlling market entry and competition in opioid formulations.
- The outcome may influence future litigation strategies and patent protections in the pharmaceutical industry.
Frequently Asked Questions
1. What patents are involved in this case?
Purdue’s patent No. 9,839,933, covering specific controlled-release oxycodone formulations, is at issue.
2. What are the main legal claims Purdue is making?
Purdue alleges direct patent infringement, seeking injunctive relief and damages. It also claims Kashiv’s product infringes its patent rights.
3. Has any court decision addressed patent validity?
No. Validity challenges are ongoing, with Kashiv arguing prior art challenges, but no final ruling has been issued.
4. What is the significance of this case for the opioid industry?
It underscores the importance of patent protection for abuse-deterrent formulations and illustrates how patent litigation can delay generic market entry.
5. Could this case set any precedents?
Potentially, especially in the area of patent validity and infringement in abuse-deterrent formulations, influencing later patent litigation strategies.
References
[1] U.S. District Court, District of Delaware. Purdue Pharma L.P. v. Kashiv Pharma LLC, Case No. 1:18-cv-00052.
[2] U.S. Patent No. 9,839,933.
[3] Court filings and docket entries, 2018-2023.
